Collaboration and License Agreements (Details) - Livmarli - USD ($) $ in Millions	1 Months Ended			3 Months Ended	9 Months Ended
	Feb. 28, 2023	Jul. 31, 2021	Apr. 30, 2021	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2021
Exclusive Licensing Agreement | CANbridge
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received			$ 11.0
Research and development funding received				$ 0.8	$ 2.2
License and other revenue					$ 5.0
Exclusive Licensing Agreement | CANbridge | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development funding received			5.0
Potential regulatory and commercial milestone payment to be received			$ 109.0
Exclusive Licensing Agreement | GC Biopharma
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received		$ 5.0
Achievement of future regulatory and commercial milestones payment	$ 2.5
Exclusive Licensing Agreement | GC Biopharma | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Achievement of future regulatory and commercial milestones payment		$ 23.0
Regulatory Approval and Commercialization | Takeda
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Company's term to receive annualized net sales						4 years